{
    "nctId": "NCT04941365",
    "briefTitle": "Quantifying Systemic Immunosuppression to Personalize Cancer Therapy",
    "officialTitle": "Quantifying Systemic Immunosuppression to Personalize Cancer Therapy",
    "overallStatus": "WITHDRAWN",
    "conditions": "Metastatic Melanoma, Metastatic Breast Cancer, Advanced Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer Stage III, Healthy",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Investigation of whether a flow cytometry blood-based MDSC quantification assay, does predict disease course in different cancer patients undergoing standard therapies including immunotherapy, chemotherapy, target therapies and surgery.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included\n* Will and ability to comply with the protocol\n* Willingness and ability to provide an adequate archival Formalin- Fixed Paraffin-Embedded (FFPE) tumor sample available for exploratory biomarker analysis\n* Age from 18 to 90 years at the time of recruitment\n* ECOG Performance Status \\< 2\n* Understanding and signature of the informed consent\n\nExclusion Criteria:\n\n* Known history of HIV infection\n* Serious neurological or psychiatric disorders\n* Pregnancy or lactation\n* Inability or unwillingness of participant to give written informed consent\n* Inability or unwillingness to be regularly followed up at the enrolling center",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}